Allarity Strengthens Stenoparib’s Path to FDA Approval with DRP® Patent Wins and Lab Certification
Event summary
- Allarity secured patents and CLIA certification for its Drug Response Predictor (DRP®) technology, solidifying stenoparib’s commercial exclusivity.
- AACR 2026 data linked higher DRP scores to longer overall survival in ovarian cancer patients, validating the test’s predictive power.
- Stenoparib’s Phase 2 trial in platinum-resistant ovarian cancer and a separate trial in small cell lung cancer are actively enrolling.
- Allarity’s in-house lab now supports companion diagnostic development and external partnerships.
The big picture
Allarity’s recent advancements position stenoparib as a differentiated PARP/WNT inhibitor with a clear regulatory pathway. The DRP® technology not only enhances patient selection but also strengthens Allarity’s intellectual property moat, a critical advantage in the competitive oncology space. The company’s ability to leverage this technology for external partnerships could further accelerate its growth.
What we're watching
- Clinical Validation
- Whether the DRP®-guided patient selection will replicate prior survival benefits in pivotal trials.
- Regulatory Strategy
- The pace at which Allarity advances stenoparib toward FDA approval with DRP® as a companion diagnostic.
- Partnership Potential
- How Allarity’s in-house lab and patented DRP® technology attract external collaborations.
Related topics